Hill Dickinson advises EMMAC on UK medical cannabis sector’s largest ever acquisition deal
Details
“Hill Dickinson has been by EMMAC’s side since it was incorporated and their trusted advice has been invaluable in helping management build EMMAC, raise capital and scale so quickly.” - Tom Allen, Finance Director, EMMAC.
In March 2021, Hill Dickinson’s Corporate, Life Sciences and Regulatory team advised longstanding client EMMAC Life Sciences on an offer that saw it successfully acquired by leading US cannabis products provider Curaleaf Holding Inc. The US $345 million acquisition marks the largest deal in the UK medical cannabis sector to date.
You can view the full story here.
This article originally featured in our Life Sciences newsletter – spring 2021 edition. If you would like to be added to our mailing list, you can subscribe via our form
